Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18844522 | 1.00 | TK1 (0.42) | TK1RNASE1LMNAALOX12ADRA1A | |
| SCHEMBL20810838 | 0.94 | RNASE1 (0.43) | TK1RNASE1LMNAALOX12ADRA1A | |
| SCHEMBL20810870 | 0.94 | RNASE1 (0.43) | TK1RNASE1LMNAALOX12ADRA1A | |
| SCHEMBL2619370 | 0.94 | RNASE1 (0.43) | TK1RNASE1LMNAALOX12ADRA1A | |
| SCHEMBL18866616 | 0.93 | RNASE1 (0.41) | RNASE1LMNAALOX12ADRA1ASMN1; SMN2 | |
| SCHEMBL18855351 | 0.93 | RNASE1 (0.41) | RNASE1LMNAALOX12ADRA1ASMN1; SMN2 | |
| SCHEMBL20810642 | 0.92 | RNASE1 (0.41) | TK1RNASE1LMNAALOX12ADRA1A | |
| SCHEMBL20810887 | 0.89 | RNASE1 (0.41) | RNASE1LMNAALOX12ADRA1ASMN1; SMN2 | |
| SCHEMBL18844510 | 0.89 | TOP2A (0.41) | — | |
| SCHEMBL18866633 | 0.89 | TOP2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | QIAGEN SCIENCES, LLC | 2022-05-26 | — | — | US | disclosed |
| US-11046726-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2021-06-29 | — | — | US | disclosed |
| US-10301346-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180208774-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2018-07-26 | — | — | US | disclosed |
| US-20170211134-A1 | THIOL-CONTAINING CLEAVE REAGENTS AND OXIDATIVE WASH | IsoPlexis Corporation | 2017-07-27 | — | — | US | disclosed |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046726-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | TK1 105/4885RNASE1 159/4885LMNA 1476/4885 |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | TK1 105/4885RNASE1 159/4885LMNA 1476/4885 |
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | TK1 105/4885RNASE1 159/4885LMNA 1476/4885 |
| US-20180208774-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | TK1 105/4885RNASE1 159/4885LMNA 1476/4885 |
| US-10301346-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | TK1 105/4885RNASE1 159/4885LMNA 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.